Stevenson, Wong & Co. partner and head of litigation and dispute resolution department Ms. Heidi Chui was invited to attend and speak on the C5’s 5th Edition Fraud, Asset Tracing & Recovery Asia Conference on 10 June 2019. Featuring a great mix of jurisdictions and topics, the conference was well received and attracted attendees from all around the globe.

At the start of the conference, Mr. Abraham Vergis from Singapore gave the opening remarks. Then The Honourable Mr. Justice Kevin Paul Zervos, Justice of Appeal of the Court of the Appeal of the High Court of Hong Kong, attended an interview by Mr. Benjamin Borsodi from Switzerland, sharing with the audience his view on fraud, asset tracing and recovery.

Our Ms. Chui was the guest speaker in the session on “Fraud and Corruption Asset Forfeiture Globally and Across Key Asia-Pacific Jurisdictions. Enforcing Court Orders” together with other panellists including Mr. Lim Chee Wee from Malaysia, Mr. Andy Liao from Mainland China, and Ms. Lim Wei Lee from Singapore. During the session, Ms. Chui shared with the audience her global asset tracing, recovery and judgment enforcement strategy and received warm welcome from the floor.

For more information, please contact our partner Ms. Heidi Chui at heidichui.office@sw-hk.com.

(中文) 2019年6月8日，史蒂文生黄律师事务所合伙人，诉讼及争议解决部主管徐凯怡律师受邀作为专业培训导师，为北京大学法学院同学们进行模拟国际仲裁课程培训，并分享仲裁经验。

若阁下想了解更多详情，请联络本所合伙人徐凯怡律师，heidichui.office@sw-hk.com。

On 6 June 2019, Stevenson, Wong & Co. (“SW”) senior associate Mr. Gordon Tsang and paralegal Mr. Arthur Hung attended the Hong Kong IPO & STO Global Cooperation Forum at Hong Kong’s Cyberport. SW senior associate Mr. Gordon Tsang was invited to deliver a speech on the topic of “Hong Kong Listing and Relevant Legal Services”. He discussed several issues including an overview of companies listed in the past year, requirements and amendments of the listing rules and the arrangements for red chip restructuring.

Please contact Mr. Gordon Tsang for further enquiry about this event.

On 31 May 2019, Stevenson, Wong & Co. (“SW”) partner Mr. Rodney Teoh and associate Mr. Kristopher Wong were invited to give a presentation to the Investment Banking Department of Guosen Securities (HK) Capital Company Limited.

Mr. Teoh and Mr. Wong gave a presentation on the topic of “IPO – Needs and New Opportunities of Corporate Finance”. In the context of PRC business coming to Hong Kong for listing, they had analysed the practical issues that the parties would face in the process of Hong Kong IPO and listing, such as the requisite listing requirements, as well as preparations and key points in the process of Hong Kong listing. Mr. Teoh and Mr. Wong had conducted in-depth exchanges and discussions with participants on relevant topics, and the training is well received by the participants.

Mr. Teoh specialized in a broad range of commercial and corporate finance work. He is a “Leading Lawyer” in capital markets and corporate and M&A in 2018 as awarded by Asialaw Profiles. He is also nominated for “Young Lawyer of the Year” in the Asian Legal Business Hong Kong Law Awards 2017.

Please contact Mr. Rodney Teoh for any enquiries or further information.

(中文) 2019年5月31日，史蒂文生黄律师事务所合伙人，诉讼及争议解决部主管徐凯怡律师，受邀出席「一带一路跨专业发展计划」暨理大创智汇“由香港 进 一带一路——领袖观点”论坛，并担任分享嘉宾。

本次论坛由香港理工大学和香港理工大学一带一路策略平台主办，并由香港理工大学会计及金融学院副院长陆海天教授主持。

本所合伙人、香港律师会一带一路委员会委员徐凯怡律师，斯里兰卡中央银行第12届理事 (2006年7月至2015年1月)、国际货币基金组织候补理事、东南亚中央银行 (SEACEN) 理事会主席、南亚区域合作联盟 (SAARC) 中央银行理事会主席Ajith Nivard CABRAAL先生，正大集团副主席、香港中华总商会荣誉主席、中华人民共和国上海浦东新区政协委员罗家顺先生以及中国银行 (香港) 有限公司副首席执行官、前中国银行江苏省分行副行长、中国银行宁波市分行行长王兵先生共同担任分享嘉宾。

若阁下想了解更多信息，请联络本所合伙人徐凯怡律师， heidichui.office@sw-hk.com

Our senior associate Mr. Gordon Tsang acted as the Joint Company Secretary of Mabpharm Limited – B (stock code: 2181) (“Mabpharm”) in its successful listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) under Chapter 18A of the Hong Kong Main Board Listing Rules.

The shares of Mabpharm were listed on the Stock Exchange on 31 May 2019. The final offer price was HK$1.50 per share and the proceeds amounted to approximately HK$1.068 billion.

Mabpharm’s pipeline contains mAbs to treat cancer and autoimmune diseases, with three biosimilars in Phase III testing: CMAB007, a proposed biosimilar of dermatology and asthma drug Xolair omalizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY); CMAB009, a proposed biosimilar of cancer drug Erbitux cetuximab from Eli Lilly and Co. (NYSE:LLY); and CMAB008, a proposed biosimilar for autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ).

Please contact Mr. Gordon Tsang for further information.